It is a link to move in the page.
To global navigation
To the text
To local navigation
To site information
Font Size
Language
news release
April 1, 2010
Teijin Pharma and Astellas Pharma Enter into Agreement for Marketing Rights of TMX-67 in China and Hong Kong — Novel Drug for Chronic Management of Hyperuricemia in Gout Patients —
March 11, 2010
Teijin Pharma Strengthens Presence in Spain’s Home Healthcare Field Furthers Business Expansion in European Market
Archives
corporate profile
Message from the President
Corporate Profile
Overview of Core Business
Global Operations
Compliance
Organization
Corporate Social Responsibility(CSR)
Synergies of the Teijin Group
Research and Development
Customer and marketing support services
History
Office Locations